logo
  

Halma Buys MK Test For GBP 44 Mln To Boost Electrical Safety Capabilities

Halma Plc (HLMA.L), a British safety equipment maker, said on Wednesday that it has acquired MK Test Systems Limited, a maker of safety-critical electrical testing technology, for a cash consideration of 44 million pounds, to be funded from Halma's existing facilities.

Marc Ronchetti, Chief Executive of Halma, said: "MK Test further enhances our capabilities in electrical safety and brings new opportunities for growth, driven by increasing safety regulation and the need to protect high value assets. Its technology plays an important role in automated electrical testing and in ensuring the integrity of electrical systems."

Post transaction, MK Test will be a standalone company within Halma's Safety sector, led by its current management.

For the 12-month period to March 2024, MK Test had registered revenue of 12.4 million pounds.

Founded in 1990, MK Test makes safety-critical electrical testing technology products used to test the integrity of high voltage electrical systems in aerospace, rail, and commercial EV industries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT